CW
Insider
Colin Walsh
DirectorColin Walsh (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 2 sales, 2 filed past the two-business-day deadline), most often in Attovia Therapeutics, Inc. Common Stock (ATTO). Across 1 priced purchase filing, the average 21-session return was +10.1% from execution and +26.2% from disclosure (delay-adjusted; derived). The largest single filing was $10.3M of ATTO (585,000 sh across 2 lots, as filed), executed Aug 5.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+10.1%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+26.2%
same 1 filings, from disclosure
Filings, ttm
2
2 buys · 2 sells · 2 late
Median delay
8d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$24.4M
shares × price, as filed
Last traded
Aug 6
Filed Aug 28
Volume by month
Buys $20.6M
Sells $3.8M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Not on file
4 filings
Sector per market data · by filing · past 12 months
Most traded names
ATTORecent filings
ATTOPURCHASE
Attovia Therapeutics, Inc. Common Stock
View filing →
$10.3M585,000 sh across 2 lots
Exec Aug 5
Filed Aug 28 · 5:38 PM ET † ATTOPURCHASE Attovia Therapeutics, Inc. Common Stock View filing → $10.3M
585,000 sh across 2 lots
Exec Aug 5
Filed Aug 13 · 9:52 PM ET † ATTOSALE Attovia Therapeutics, Inc. Common Stock View filing → $1.9M
90,151 sh across 3 lots
Exec Aug 5
Filed Aug 28 · 5:38 PM ET † ATTOSALE Attovia Therapeutics, Inc. Common Stock View filing → $1.9M
90,151 sh across 3 lots
Exec Aug 5
Filed Aug 13 · 9:52 PM ET †